GlobeNewswire

Inspirata Announces First Annual Executive Exchange Conference

Share

Inspirata assembles lineup of top industry thought leaders including digital & molecular pathology, oncology, research, surveillance and health system executives, to discuss how to propel practical advances in cancer care and research.

Tampa, Florida, July 02, 2019 (GLOBE NEWSWIRE) --

Leading provider of tissue diagnostics and cancer care insight solutions, Inspirata, announced today its First Annual Executive Exchange, being held from July 31 – August 2, 2019 at the Sapphire Falls Resort at Universal Studios in Orlando, Florida.  The conference’s theme is “Practical Advances in Cancer Care & Research: Bringing the Cancer Moonshot Back to Earth” and will bring together thought leaders of varied disciplines to focus on the data, technologies, clinical processes and collaboration needed to propel practical advances in cancer care. 

Inspirata’s Executive Exchange will feature collaborative discussions from some of the industry’s top thought leaders in areas of oncology, pathology, molecular diagnostics, research, technology, surveillance, health systems, payers and the economic and investment market.  “The need to collect patient-consented genomic, pathology, and imaging data and correlate it with clinical data, including epidemiologic, treatment and outcomes data, for all cancer patients, under a single accessible data bank is the number one challenge impeding advances in cancer care,”  states Keynote speaker, Michael A. Caligiuri, MD, President, City of Hope National Medical Center - Deana and Steve Campbell Physician-in-Chief Distinguished Chair.  “Inspirata’s Executive Exchange brings the most recent ideas and developments to enhance data sharing among stakeholders to address this issue.”  Dr. Caligiuri will present on the topic of rapid advances in precision technology innovation and sustainable strategies for genetic and molecular medicine. 

“The cancer care journey is composed of many disciplines that infrequently get the opportunity to collaborate and understand how they can advance the overall care process for patients.  Likewise, clinical and research professionals often lack a complete understanding of the others’ needs and restraints in progressing therapy advancement,” states Satish Sanan, CEO of Inspirata.  “The Inspirata Executive Exchange is designed to present a 360-degree perspective on advancing cancer care in an interactive and engaging format.  Inspirata believes that communication is at the heart of innovation and facilitating collaboration across the varied disciplines of the cancer care journey is a needed catalyst to treatment innovation.”

“The drive to cure cancer through therapy advancement requires relevant and real-world data from across the cancer care journey.  It requires precision data, patient involvement and the ability to surface meaningful insights to all care cycle constituents,” states Greg Tennant, Chief Strategy & Marketing Officer for Inspirata.  “Our industry has struggled with the ability to surface meaningful data, match patients for clinical trials and legitimize the use of data for the advancement of care.  Inspirata’s leadership in hosting the Executive Exchange on the advancement of cancer therapy is focused on bridging these gaps to drive real progress.”

The Executive Exchange is an invitation only event for cancer industry thought leaders.  If you are a cancer industry thought leader and wish to attend the Executive Exchange, please submit a registration request at https://go.inspirata.com/exec-exchange-2019/ for consideration.  There are no registration costs for approved attendees and no fees paid to our stellar line-up of speakers.  The official social media hashtag for the Inspirata Executive Exchange will be #iee2019. The Executive Exchange is not a commercial event.


About Inspirata, Inc.
Inspirata®, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. Our comprehensive cancer informatics solutions bring disparate data together throughout the entire cancer care journey to drive informed decisions that improve survivorship. 

Inspirata has assembled the most advanced and proven technologies to address the complex challenges of delivering cancer care and conducting ground-breaking research. We combine leading digital pathology solutions with automated cancer registry solutions, comprehensive cancer informatics and advanced patient engagement tools to bring users the broadest oncology informatics platform available globally. For more information, please visit www.inspirata.com or contact info@inspirata.com.

Attachments

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

FRO - Invitation to Q3 2019 Results Conference Call and Webcast19.11.2019 13:16:00 CETPress release

Frontline Ltd.’s preliminary third quarter 2019 results will be released on Wednesday November 27 2019, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontline.bm ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at www.frontline.bm and follow the “Webcast” link. b. Conference Call Participant dial-in telephone numbers: Norway +47 2156 3162 Norway toll free 800 10392 UK +44 (0) 203 009 5710 UK Toll Free 0 800 376 7425 USA +1 917 720 0178 USA Toll Free 866 869 2321 Conference ID 5598374 Participants will be asked for their full name & Conference ID. A Q&A session will be held after the teleconference/webcast. Information on how to submit questions will be given at the beginning of the session. The presentation material which will be used in th

Oasmia offentliggör prospekt i samband med företrädesemission om cirka 399 MSEK samt uppdaterad information som återfinns i prospektet19.11.2019 13:00:00 CETPressemelding

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. Styrelsen i Oasmia Pharmaceutical AB (“Oasmia” eller ”Bolaget”) meddelande den 11 november 2019 om genomförandet av en nyemission av aktier med företrädesrätt för Oasmias befintliga aktieägare om cirka 399 MSEK ("Företrädesemissionen"). Bolaget har med anledning av Företrädesemissionen upprättat ett prospekt som idag godkänts och registrerats av Finansinspektionen. Offentliggörande av prospekt För fullständig information om Företrädesemissionen hänvisas till det prospekt som upprättats av Bolaget samt idag godkänts och registrerats av Finansinspektionen per dagens datum.

Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus19.11.2019 13:00:00 CETPress release

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). See the section “IMPORTANT INFORMATION” below. The board of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) announced on 11 November 2019 to carry out a new issue of shares with preferential rights for Oasmia’s shareholders of approximately SEK 399 million (the “Rights Issue”). As a result of the Rights Issue, the Company has prepared a prospectus, which has been approved and registered by the Swedish Financial Supervisory Authority today. Publication of the prospectus For complete information on the Rights Issue, refer to the prospectus that has been prepared by Oasmia as well as appro

Medtronic Reports Second Quarter Financial Results19.11.2019 12:45:00 CETPress release

Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%; Free Cash Flow of $1.6 Billion Grew 66% Company Raises FY20 EPS Guidance DUBLIN, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019. The company reported second quarter worldwide revenue of $7.706 billion, an increase of 3.0 percent as reported or 4.1 percent on an organic basis, which adjusts for a $97 million negative impact from foreign currency and a $16 million contribution from the company’s acquisition of Titan Spine, which is reported in the Spine division in the Restorative Therapies Group. As reported, second quarter GAAP net income and diluted earnings per share (EPS) were $1.364 billion and $1.01, respectively. As detailed in the financial schedules included through the link at the end of t

Avenir LNG collaborates with Golar Power on developing small-scale LNG distribution in Brazil19.11.2019 12:00:00 CETPress release

London, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Avenir LNG Limited (“Avenir”) wishes to announce that it will collaborate with Golar Power Limited (“Golar Power”) in developing the small-scale LNG market in Brazil. Avenir’s second 7,500 cbm LNG Carrier will be used to deliver LNG to various ports across Brazil upon delivery. The vessel will also offer ship-to-ship bunkering capability as part of Avenir’s global multi-nodal bunkering solution; adding to the Colombian, Mediterranean and Malaysian nodes which the company currently offers. Commenting on the collaboration with Golar Power, Andrew Pickering, Chief Executive Officer of Avenir LNG Limited, said, “This is another step in our strategy where we are working closely with a shareholder in leveraging its FSRU platform to develop small-scale LNG distribution and bunkering in key developing markets.” Commenting on the collaboration with Avenir LNG, Eduardo Antonello, Chief Executive Officer of Golar Power Limited, said, “Accessing small-scal